Parenteral formulation of metolazone

Details Parenteral formulation of metolazone Parenteral formulation of metolazone

1991-01-07

1992-06-23

Page, Thurman K.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

514312, 514869, 544231, 544288, C07D23972, A01N 4342, A61K 3147

Patent

active

051241528

ABSTRACT:
There are described pharmaceutical compositions comprising aqueous solutions of 7 c l r - ,2,3,4-tetrahydro-2-methyl-3-2-methylphenyl)-4-oxo-6-quinazolinesulfonamid e. ethanol and a cosolvent selected from propylene glycol or polyethylene glycols suitable for parenteral administration to a patent suffering from refractory edema.

REFERENCES:
patent: 4472380 (1984-09-01), Harris et al.
A. I. Cohen, et al., Physiological Disposition of a New Diuretic, .sup.14 C-Metolazone, in Dogs. (J. Pharmaceutical Sciences (1973), vol. 62, 931-936).
E. J. Belair, The Renal Pharmacology of Metolazone, 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone, (Research Communications in Chemical Pathology and Pharmacology, (1971), vol. 2, No. 1).

Affiliated with

Also associated with

Rating

Parenteral formulation of metolazone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Parenteral formulation of metolazone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral formulation of metolazone will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-931791